Semaglutide In the SELECT trial, semaglutide 2.4 mg reduced a composite renal endpoint ( 50% eGFR decline, macroalbuminuria onset, or need for renal replacement therapy) by 22% vs
Maven Clinic's specialized healthcare professionals are in your corner
We also investigated the changes in HbA1c and body weight after treatment with semaglutide, and found that HbA1c decreased by 0.75% and body weight reduced by 2.80 kg, indicating that weight loss and SBP reduction were synchronized
And, I think thats worthwhile
This product stands out for its plant-based formulation, suitable for vegetarians and vegans, and for its 60-day treatment duration, ideal for continuous protection
While it is still in clinical development, trial data provides insights into how its typically studied